Precision NeuroMed, Inc.
Clinical-stage biotechnology company developing an integrated platform for loco-regional brain therapy. The platform combines convection-enhanced delivery (CED) hardware, image-based treatment-planning software, and targeted therapeutics to bypass the blood–brain barrier and deliver high local drug concentrations for diseases such as glioblastoma.
Industries
N/A
Nr. of Employees
small (1-50)
Precision NeuroMed, Inc.
Products
Integrated loco-regional brain therapy platform
An integrated platform combining CED hardware (microinfusion catheter), image-based treatment-planning software, and support for multiple therapeutic modalities to enable direct delivery of therapeutics to brain tissue.
Clinical-stage targeted protein therapeutic (receptor-targeted)
Development-stage receptor-targeted cytotoxic protein therapy aimed at tumor cell populations in the brain, being advanced with loco-regional delivery to achieve therapeutic concentrations at the disease site.
Integrated loco-regional brain therapy platform
An integrated platform combining CED hardware (microinfusion catheter), image-based treatment-planning software, and support for multiple therapeutic modalities to enable direct delivery of therapeutics to brain tissue.
Clinical-stage targeted protein therapeutic (receptor-targeted)
Development-stage receptor-targeted cytotoxic protein therapy aimed at tumor cell populations in the brain, being advanced with loco-regional delivery to achieve therapeutic concentrations at the disease site.
Services
Patient-specific planning software that integrates MRI anatomy with fluid and drug flow models to generate pre- and intra-operative infusion plans.
Patient-specific planning software that integrates MRI anatomy with fluid and drug flow models to generate pre- and intra-operative infusion plans.
Expertise Areas
- CNS loco-regional drug delivery
- Neurosurgical device and catheter development
- Treatment-planning software and AI-driven dosing models
- Clinical-stage therapeutic development for brain tumors
Key Technologies
- Convection-enhanced delivery (CED)
- Microinfusion catheter technology
- MRI-based treatment planning (MR-DTI, T2)
- Predictive drug-distribution algorithms
News & Updates
Announcement that an investigational therapy received Orphan Drug Designation from the U.S. FDA for glioblastoma; describes use of CED to deliver therapeutic concentrations to tumor-infiltrated brain regions.
Acquisition of a 510(k)-cleared molecular flow simulation software used for pre- and intra-operative planning and to model fluid distribution; to form the foundation of the company's treatment-planning software.
Announcement of advisory board appointment; notes experience in regulatory and clinical strategy and intended role advising on remanufacturing, regulatory clearance, and commercialization.
Announcement of advisory board appointment; notes prior FDA leadership in cellular and gene therapies and historical role in discovery of receptor-targeted agents for glioblastoma.
Announcement of an appointment to lead clinical software and applications, noting prior experience co-founding a precision drug-delivery company and involvement with FDA clearance of software.
U.S. FDA granted Orphan Drug Designation for the company's investigational glioblastoma therapy.
Announcement that an investigational therapy received Orphan Drug Designation from the U.S. FDA for glioblastoma; describes use of CED to deliver therapeutic concentrations to tumor-infiltrated brain regions.
Acquisition of a 510(k)-cleared molecular flow simulation software used for pre- and intra-operative planning and to model fluid distribution; to form the foundation of the company's treatment-planning software.
Announcement of advisory board appointment; notes experience in regulatory and clinical strategy and intended role advising on remanufacturing, regulatory clearance, and commercialization.
Announcement of advisory board appointment; notes prior FDA leadership in cellular and gene therapies and historical role in discovery of receptor-targeted agents for glioblastoma.
Announcement of an appointment to lead clinical software and applications, noting prior experience co-founding a precision drug-delivery company and involvement with FDA clearance of software.
U.S. FDA granted Orphan Drug Designation for the company's investigational glioblastoma therapy.